Sign in

CIK 0001680581

  • Non-accelerated filer
  • Smaller reporting company

Fulcrum Therapeutics, Inc.

Sign in to watch
Ticker
FULC
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
474839948
Phone
+1 617-651-8851
Business address
26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2020-03-02 Cadavid Diego SVP Clinical Development Sale −315 $18.13 $6K 66,785
2020-02-24 Thomson Peter G. VP Finance & Accounting Sale −2,648 $16.18 $43K 30,923
2020-02-24 Thomson Peter G. VP Finance & Accounting Sale −2,102 $17.43 $37K 28,821
2020-02-24 Thomson Peter G. VP Finance & Accounting Sale −250 $18.61 $5K 28,571
2020-02-19 Gould Robert J Sale −2,500 $20.00 $50K 554,845
2020-02-19 Wallace Owen B. Chief Scientific Officer Exercise or conversion +6,088 $7.84 $48K 133,176
2020-02-19 Wallace Owen B. Chief Scientific Officer Sale −6,088 $20.00 $122K 127,088
2020-02-19 Wallace Owen B. Chief Scientific Officer Exercise or conversion · Stock Option (right to buy) −6,088 88,126
2020-02-03 Cadavid Diego SVP Clinical Development Sale −2,143 $17.33 $37K 68,928
2020-01-23 Stuart Bryan Chief Operating Officer Grant or award · Stock Option (right to buy) +105,000 105,000
2020-01-23 Cadavid Diego SVP Clinical Development Grant or award · Stock Option (right to buy) +55,440 55,440
2020-01-23 Thomson Peter G. VP Finance & Accounting Sale −4,738 $17.17 $81K 33,833
2020-01-23 Thomson Peter G. VP Finance & Accounting Sale −262 $18.05 $5K 33,571
2020-01-23 Thomson Peter G. VP Finance & Accounting Grant or award · Stock Option (right to buy) +33,100 33,100
2020-01-23 Gould Robert J President & CEO Grant or award · Stock Option (right to buy) +200,000 200,000
2020-01-23 Wallace Owen B. Chief Scientific Officer Grant or award · Stock Option (right to buy) +58,900 58,900
2020-01-02 Dorton Katina Director Grant or award · Stock Option (right to buy) +18,571 18,571
2019-07-22 GLAXOSMITHKLINE PLC 10% owner Conversion +1,785,714 1,785,714
2019-07-22 GLAXOSMITHKLINE PLC 10% owner Conversion · Series B Preferred Stock −12,500,000 0
2019-07-22 Sanofi 10% owner Conversion +464,285 464,285

Page 13 of 15 · 291 trades